Market Research Logo

Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

About epilepsy

Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.

Technavio's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.

Technavio's report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
Other prominent vendors
  • AbbVie
  • Janssen Pharmaceuticals
  • Lundbeck
  • Meda
  • Novartis
  • Roche
  • Shire
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Upsher-Smith
  • Valeant Pharmaceuticals
Market driver
  • Unmet medical needs
  • For a full, detailed list, view our report
Market challenge
  • Patent expiry
  • For a full, detailed list, view our report
Market trend
  • Reformulation of marketed drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Epilepsy Drugs Market in Europe 2015-2019

Technavio recognizes the following companies as the key players in the Epilepsy Drugs Market in Europe: Eisai, UCB Pharma, Pfizer and GlaxoSmithKline

Other Prominent Vendors in the market are: AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, and Valeant Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “Reformulated medicines usually have better tolerability, reduced dosing regimen, and decreased developmental costs than original drugs. Few vendors are focusing on developing such drugs instead of manufacturing new drugs. For instance, Neurontin by Pfizer, Keppra by UCB, and Trobalt by GlaxoSmithKline are film-coated tablets that were recently launched in the market.”

According to the report, growing patient population will lead to an increase in the consumption of anti-epileptic drugs. The market has significant levels of unmet medical needs. Currently, there are no safe and efficient disease-modifying drugs present in the market. Available drugs have many side effects, which decreases patient compliance. Any drug that can completely cure the disease will drive the market.

Further, the report states that patent expiries of major branded drugs will decrease their market sales. This will decrease the market revenue of innovator drugs, paving the way for their generic forms.

Companies Mentioned

Eisai, UCB Pharma, Pfizer, GlaxoSmithKline, AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Epilepsy: An overview
    • About the disease
    • Types of epilepsy
    • Signs and symptoms
    • Diagnosis
    • Epidemiology
    • Economic burden
      • Table Cost per person in Europe 2010
  • Pipeline portfolio
    • Table Pipeline portfolio
    • Key information of few pipeline candidates
  • Market landscape
    • Market overview
      • Table Epilepsy drugs market in Europe 2014-2019 ($ millions)
      • Table Epilepsy drugs market in Europe 2014
    • Epilepsy drugs market in Germany
      • Table Epilepsy drugs market in Germany 2014-2019 ($ millions)
    • Epilepsy drugs market in the UK
      • Table Epilepsy drugs market in the UK 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by generation of drugs
    • Segmentation of epilepsy drugs market in Europe by generation of drugs
      • Table Segmentation of epilepsy drugs market in Europe by generation of drugs
  • Market drivers
    • Unmet medical needs
    • Rise in patient population
    • Promising drug pipeline
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Expiry of patents
    • Stringent regulatory guidelines
    • Social stigma associated with epilepsy
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Reformulation of marketed drugs
    • Emergence of new-generation anti-epileptic drugs
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Eisai: Key takeaways
      • Table Eisai: Fycompa product profile
      • Table Eisai: Revenue of Fycompa in EMEA 2013 and 2014 ($ millions)
      • Table Eisai: Inovelon product profile
      • Table Eisai: Revenue of Inovelon in EMEA 2013 and 2014 ($ millions)
      • Table Eisai: Zebinix product profile
      • Table Eisai: Revenue of Zebinix in EMEA 2013 and 2014 ($ millions)
      • Table Eisai: Zonegran product profile
      • Table Eisai: Revenue of Zonegran 2013 and 2014 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
      • Table GlaxoSmithKline: Lamictal product profile
      • Table GlaxoSmithKline: Revenue of Lamictal in Europe 2011-2014 ($ millions)
      • Table GlaxoSmithKline: Trobalt product profile
      • Table Pfizer: Key takeaways
      • Table Pfizer: Lyrica product profile
      • Table Pfizer: Revenue of Lyrica 2011-2014 ($ millions)
      • Table Pfizer: Neurontin product profile
      • Table Pfizer: Revenue of Neurontin 2011-2013 ($ millions)
      • Table UCB: Key takeaways
      • Table UCB: Keppra product profile
      • Table UCB: Revenue of Keppra in Europe 2011-2014 ($ millions)
      • Table UCB: Vimpat product profile
      • Table UCB: Revenue of Vimpat in Europe 2011-2014 ($ millions)
    • Other prominent vendors
  • Key vendor analysis
    • Eisai
    • GlaxoSmithKline
    • Pfizer
    • UCB
      • Table UCB: Product segmentation by revenue 2014
      • Table UCB: Product segmentation by revenue 2013 and 2014
      • Table UCB: Geographical segmentation by revenue 2014
      • Table UCB: Geographical segmentation by revenue 2013 and 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report